` 301075 (Tibet Duo Rui Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

T
301075
vs
S
Shanghai Composite

Over the past 12 months, Tibet Duo Rui Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +219% compared to the Shanghai Composite's +24% growth.

Stocks Performance
301075 vs Shanghai Composite

Loading
301075
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
301075 vs Shanghai Composite

Loading
301075
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
301075 vs Shanghai Composite

Loading
301075
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Tibet Duo Rui Pharmaceutical Co Ltd vs Peers

Shanghai Composite
301075
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Tibet Duo Rui Pharmaceutical Co Ltd
Glance View

Market Cap
5B CNY
Industry
Pharmaceuticals

Tibet Duo Rui Pharmaceutical Co., Ltd. engages in research and development, manufacture, and sale of chemical preparations and their raw materials. The company is headquartered in Qamdo, Xizang and currently employs 299 full-time employees. The company went IPO on 2021-09-29. The firm's core product is sodium acetate ringer injection, which is mainly used to supplement body fluid, regulate electrolyte balance and correct acidosis. The firm's products also include its own products, compound electrolyte injection, compound mannitol injection and cefotaxime sodium for injection.

Intrinsic Value
7.7 CNY
Overvaluation 88%
Intrinsic Value
Price
T
Back to Top